GlassScriptPhysician profile
Jordan Kassoff
NPI 1407849292
$97,563.52
in general payments reported to CMS, 2019-2025
28 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,431 · 2020: $6,408 · 2021: $17K · 2022: $15K · 2023: $12K · 2024: $20K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $33K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,765 · Food and Beverage: $5,952 · Consulting Fee: $1,700 · Travel and Lodging: $291 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $33,356.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,765.00 |
| Food and Beverage | $5,951.86 |
| Consulting Fee | $1,700.00 |
| Travel and Lodging | $290.55 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $37,790.82 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $32,074.96 | 2019-2022 | |
| Abbvie INC. | $10,926.54 | 2022-2025 | |
| Oyster Point Pharma, INC. | $9,438.97 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sight Sciences, INC. | $2,559.09 | 2022-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Sun Pharmaceutical Industries INC. | $940.93 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $803.37 | 2021-2025 | Acthar |
| Dompe US, INC. | $584.21 | 2020-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $581.30 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $375.91 | 2020-2025 | Tryptyr, Rocklatan, Eysuvis |
| Ocular Therapeutix, INC. | $272.73 | 2019-2023 | Dextenza |
| Kala Pharmaceuticals, INC. | $267.56 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $256.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $125.60 | 2020-2023 | |
| Biotissue Holdings INC. | $107.98 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $85.13 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $68.89 | 2019-2023 | Lipiflow System Activator II (Disposable |
| Thea Pharma INC. | $68.32 | 2023-2025 | Iyuzeh |
| Omeros Corporation | $33.92 | 2019 | |
| Eyevance Pharmaceuticals LLC | $31.21 | 2021-2022 | |
| Eyepoint US, INC. | $27.09 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.66 | 2024 | Ultomiris |
| Spark Therapeutics, INC. | $24.59 | 2022 | |
| Merz Pharmaceuticals, LLC | $21.70 | 2025 | Xeomin |
| Shire North American Group INC | $21.26 | 2019 | |
| Tearlab Corp | $18.11 | 2023 | Tearlab Osmolarity System |
| Rayner Intraocular Lenses Limited | $16.46 | 2023 | Omidria, Rayone Spheric, Rayone Emv |
| Harrow Eye, LLC | $14.51 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Kassoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.